ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1351

Mortality of Rheumatoid Arthritis Patients, Treated to Target at Low Disease Activity: 17-years Follow-up of the BeSt Cohort

Johanna M Maassen1, YPM Goekoop 2, JHLM van Groenendael 3, WF Lems 4, PJSM Kerstens 5, Thomas Huizinga 6 and CF Allaart 1, 1Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, 2Haga Hospital, 's-Gravenhage, Netherlands, 3Reumazorg Zuid West Nederland, Rozendaal, Netherlands, 4Amsterdam UMC, Amsterdam, Netherlands, 5Westfriesgasthuis, Hoorn, Netherlands, 6Leiden University Medical Center, Leiden, Netherlands

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: morbidity and mortality and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis is known to be associated with increased mortality over the years when compared to the general population. In the BeSt study, 508 patients were treated to target (Disease Activity Score ≤2.4) for 10 years between April 2000 and August 2012. At the end of the initial study follow-up observed mortality in the BeSt cohort was similar to mortality in the general population. In the current study we evaluated the mortality in the BeSt cohort after 17 years follow-up and compared it to the general Dutch population.

Methods: In the BeSt study 508 patients diagnosed with early RA were randomized to four initial treatment strategies: 1. Sequential monotherapy; 2. Step-up combination therapy; 3. Initial combination therapy with prednisone; or 4. Initial combination therapy with infliximab. During the 10-year follow-up period treatment was aimed at low disease activity (DAS ≤2.4) and adjusted every three months if necessary. After 10-years patients were treated and followed-up according to regular care. We explored mortality through the Dutch state registry for mortality (Centrum voor Familiegeschiedenis) and treating rheumatologist. Mortality in the BeSt cohort was compared to the general Dutch population (Statistics Netherlands) matched by gender, age, and calendar year using the standardized mortality ratio (SMR). Kaplan-Meier curves and the log-rank test were used to compare survival among the initial treatment strategies.

Results: The mean duration of follow-up in alive patients was 17 years (range 16-18). In total, 143 patients died (28%) compared to a total of 105 (21%) expected deaths in the reference population. The overall SMR after 17 years was 1.37 (95% CI: 1.16-1.61). Within the study population, no statistically significant difference in survival-curves was observed between the four initial treatment strategies (log-rank p=0.76) (table 1, and figure 1).

Conclusion: After (mean) 17 years of follow-up there was increased mortality in the BeSt study cohort compared to the general Dutch population. We observed no difference in survival among the four treatment strategies.

Figure 1. Survival curves per initial treatment strategy


Disclosure: J. Maassen, None; Y. Goekoop, None; J. van Groenendael, None; W. Lems, None; P. Kerstens, None; T. Huizinga, Abblynx, 2, 5, 8, Abbott, 2, 5, 8, Biotest AG, 2, 5, 8, Boehringer Ingelheim, 2, 5, 8, Boeringher Ingelheim, 2, 5, 8, Bristol-Myers Squibb, 2, 5, 8, Crescendo Bioscience, 2, 5, 8, Eli Lilly, 2, 5, 8, Epirus, 2, 5, 8, Galapagos, 2, 5, 8, Janssen, 2, 5, 8, Merck, 2, 5, 8, Novartis, 2, 5, 8, Nycomed, 2, 5, 8, Pfizer, 2, 5, 8, Roche, 2, 5, 8, Sanofi, 2, 5, Sanofi-Aventis, 2, 5, 8, Takeda, 2, 5, 8, UCB, 2, 5, 8, Zydus, 2, 5, 8; C. Allaart, None.

To cite this abstract in AMA style:

Maassen J, Goekoop Y, van Groenendael J, Lems W, Kerstens P, Huizinga T, Allaart C. Mortality of Rheumatoid Arthritis Patients, Treated to Target at Low Disease Activity: 17-years Follow-up of the BeSt Cohort [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/mortality-of-rheumatoid-arthritis-patients-treated-to-target-at-low-disease-activity-17-years-follow-up-of-the-best-cohort/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mortality-of-rheumatoid-arthritis-patients-treated-to-target-at-low-disease-activity-17-years-follow-up-of-the-best-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology